Search

Your search keyword '"Loschi, Michael"' showing total 302 results

Search Constraints

Start Over You searched for: Author "Loschi, Michael" Remove constraint Author: "Loschi, Michael"
302 results on '"Loschi, Michael"'

Search Results

2. Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT

3. Transplantation for myelofibrosis patients in the ruxolitinib era: a registry study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire

5. Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registry

6. Correction: Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT

7. Allogeneic hematopoietic stem cell transplantation for adults with therapy-related acute myeloid leukaemia: a retrospective multicentre study on behalf of the SFGM-TC

9. Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia

10. Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS

11. Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study)

13. Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry

14. Pooled allogeneic faecal microbiota MaaT013 for steroid-resistant gastrointestinal acute graft-versus-host disease: a single-arm, multicentre phase 2 trial

15. Enforced gut homing of murine regulatory T cells reduces early graft-versus-host disease severity

16. Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

17. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study

18. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

19. Retinoic acid signaling acts as a rheostat to balance Treg function

20. Dendritic Cell Expression of Retinal Aldehyde Dehydrogenase-2 Controls Graft-versus-Host Disease Lethality

23. Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT

24. Comparison of clinical outcomes of several risk stratification tools in newly diagnosed AML patients: A real‐world evidence in our current therapeutic era

25. Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses

26. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort

27. Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party

29. Real World Data of Axicabtagene Ciloleucel As Second Line Therapy for Patients with Large B Cell Lymphoma: First Results of a Lysa Study from the French Descar-T Registry

30. Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

32. Late relapse after hematopoietic stem cell transplantation for acute leukemia: a retrospective study by SFGM-TC

33. Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD

34. Non-Relapse Mortality after CAR T-Cell therapy for Large B-Cell Lymphoma: A LYSA Study from the DESCAR-T Registry

35. Clinical and immune features of human parvovirus B19 infection in allogeneic stem cell transplantation recipients: A retrospective monocentric study

36. SARS-CoV-2 vaccination in 361 non-transplanted patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria

37. PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)

38. P1038: TL-895, A FIRST-IN-CLASS, COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) FOR THE TREATMENT OF MYELOFIBROSIS (MF) PATIENTS (PTS) WITH SEVERE THROMBOCYTOPENIA (PLATELETS (PLTS) <50 K/UL)

39. P1146: TRANSFUSION NEEDS AFTER CD19 CAR T-CELLS FOR LARGE B-CELL LYMPHOMA: PREDICTIVE FACTORS AND IMPACT ON OUTCOME. A DESCAR-T STUDY.

40. The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease

41. Efficacy and tolerance of brexucabtagene autoleucel in adults with R/R B-ALL: a GRAALL study from the DESCAR-T registry

43. Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production

44. Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA

45. Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Therapy-Related Acute Myeloid Leukemia: a Retrospective Multicentre Study on behalf of the SFGM-TC

47. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

48. Real‐life challenges using personalized prognostic scoring systems in acute myeloid leukemia

49. Comparison of Risk Stratification Tools (ELN-2022, ELN-2017, Lindsley et al., Papaemmanuil et al. and ALFA classifier) in Predicting Outcomes of Patients with Acute Myeloid Leukemia

50. Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry

Catalog

Books, media, physical & digital resources